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systemAbstract Hypertension is the most common cardiovascular disease worldwide. Moreover, man-
agement of hypertension requires long-term treatment that may result in poor patient compliance
with conventional dosage forms due to greater frequency of drug administration. Although there is
availability of a plethora of therapeutically effective antihypertensive molecules, inadequate patient
welfare is observed; this arguably presents an opportunity to deliver antihypertensive agents
through a different route. Ever since the transdermal drug delivery came into existence, it has
offered great advantages including non-invasiveness, prolonged therapeutic effect, reduced side
effects, improved bioavailability, better patient compliance and easy termination of drug therapy.
Attempts were made to develop the transdermal therapeutic system for various antihypertensive
agents, including b-blockers, an important antihypertensive class. b-blockers are potent, highly
effective in the management of hypertension and other heart ailments by blocking the effects of
normal amounts of adrenaline in the heart and blood vessels. The shortcomings associated with
b-blockers such as more frequent dose administration, extensive ﬁrst pass metabolism and variable
bioavailability, make them an ideal candidate for transdermal therapeutic systems. The present arti-
cle gives a brief view of different b-blockers formulated as transdermal therapeutic system in detail
to enhance the bioavailability as well as to improve patient compliance. Constant improvement in
this ﬁeld holds promise for the long-term success in technologically advanced transdermal dosage
forms being commercialized sooner rather than later.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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The potential of using intact skin as the route of drug admin-
istration has been known for several years. The inspiration for
using skin for the delivery of drug is obtained from ancient
times. In recent times, development of transdermal delivery
system started in 1970s, and in 1979, the ﬁrst transdermal
patch of scopolamine was approved by USFDA for the treat-
ment of motion sickness and later on a nitroglycerine patch
was marketed for the management of angina pectoris (Ahad
et al., 2010). The transdermal therapeutic system (TTS)
prevents many of the problems associated with oral and intra-
venous routes. Major advantages provided by TTS include
improved bioavailability, more uniform plasma levels, longer
duration of action resulting in less dosing frequency, reduced
side effects, and improved therapy due to the maintenance of
plasma levels (Ahad et al., 2009; Ahad et al., 2014). Advances
in modern technologies are resulting in a larger number of
drugs being delivered transdermally including conventional
hydrophobic small molecule drugs, hydrophilic drugs and
macromolecules. There is no potential limit for the therapeutic
area for the development of transdermal systems. A number of
TTS for different drugs are now in the market including those
for nicotine, clonidine, testosterone, oxybutinin, fentanyl, lido-
caine and estradiol. The general acceptability of transdermal
products by patients is very high, which is also evident from
the increasing market for transdermal products. The transder-
mal market is estimated to represent today, worldwide, ca. $9.5
billion (Aqil et al., 2006).
Hypertension is usually deﬁned by the presence of a chronic
elevation of systemic arterial pressure above a certain thresh-
old value. This is a progressive cardiovascular syndrome aris-
ing from complex and interrelated etiologies. Progression is
strongly associated with functional and structural cardiac
and vascular abnormalities that damage the heart, kidneys,
brain, vasculature, and other organs and lead to premature
morbidity and death (Giles et al., 2009). Global burden of dis-
ease study reported that there were 5.2 million deaths from
cardiovascular diseases in economically developed countries
and 9.1 million deaths from the same causes in developing
countries (Jain and Joshi, 2007). Worldwide prevalenceestimates for hypertension may be as much as 1 billion individ-
uals and approximately 7.1 million deaths per year may be
attributable to hypertension (Kearney et al., 2005; Chockalin-
gam et al., 2006; Alderman, 2007). Therefore cost effective ap-
proaches to optimally control blood pressure are very much
needed (Selvam et al., 2010). There are many categories of
antihypertensive agents, which lower blood pressure by differ-
ent means; among the antihypertensive, most important and
most widely used are the thiazide diuretics, b-blockers, the
ACE inhibitors, calcium channel blockers and angiotensin II
receptor antagonists.
In the 1980s and 1990s, b-blockers were listed as preferred
ﬁrst-line antihypertensive drugs along with diuretics in na-
tional hypertension guidelines. Subsequent updates of the
guidelines favored diuretics as initial therapy and classiﬁed
all other categories of antihypertensive medications to be alter-
natives to diuretics (Moser, 1997; Che et al., 2009). Although
b-blockers remain alternative ﬁrst-line drugs in the latest
guidelines (Chobanian et al., 2003), they are the preferred anti-
hypertensive agents for patients with cardiac disease. It is well
established that b-blockers are effective in treating patients
with all grades of hypertension and because these drugs are
potentiated by thiazide diuretics, it is general policy to use this
combination in most patients with hypertension. Although the
b-blockers have many individual side effects, when compared
to many other antihypertensive drugs, they are remarkably
free of a number of troublesome side effects that have bedev-
iled the treatment of hypertension for many years. The drows-
iness, lethargy, and nasal congestion so common with
methyldopa, the interference with sexual function and postural
hypotension frequently encountered with the adrenergic neu-
rone blocking drugs, and the serious withdrawal phenomena
found with clonidine are not frequent manifestations of
b-blocker therapy (O’Brien, 1978).
The shortcomings associated with conventional oral deliv-
ery of b-blockers can be potentially minimized by novel drug
delivery systems including transdermal dosage forms. How-
ever, so far none of the b-blocker drugs have been marketed
as transdermal delivery systems. Nevertheless, there have been
noteworthy research endeavors worldwide at the laboratory
level to investigate the skin permeation and to develop
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(PP), Atenolol (AT), Metoprolol (MP), Bupranolol (BPL),
Labetalol hydrochloride (LHCL), Carvedilol (CVD), Timolol
maleate (TM) and Bisoprolol (BSP). Several studies have been
investigated to develop transdermal systems of anti hyperten-
sive drugs. Recently, Ahad et al., reviewed details of transder-
mal research speciﬁcally on calcium channel blockers for the
management of hypertension (Ahad et al., 2013a), while
Gu¨ngo¨randOzsoy,2012andSelvametal.havedoneabriefover-
view on the different antihypertensive drugs delivered via skin in
the literature (Selvam et al., 2010; Gu¨ngo¨r and Ozsoy, 2012).
Antecedently, Aqil et al. reviewed details of the studies focused
on the transdermal delivery of b-blockers (Aqil et al., 2006).
This review shows an outline of the transdermal research in
the area of b-blockers reported in various pharmaceutical jour-
nals. The advances and innovations in the transdermal delivery
of b-blockers for the management of hypertension are dis-
cussed in the text and a summary is presented in Table 1.2. Nonselective b-blockers (b1 and b2)
2.1. Propranolol
PP is a nonselective b-adrenergic blocking agent. It inhibits
response to adrenergic stimuli by competitively blocking b-
adrenergic receptors within the myocardium and within bron-
chial and vascular smooth muscle. It has been widely used in
the treatment of hypertension and many other cardiovascular
disorders. PP is subject to an extensive and highly variable he-
patic ﬁrst-pass metabolism following oral administration, with
a reported systemic bioavailability of between 23% (Ahad
et al., 2011; Rao et al., 2003; Dey et al., 2007). The peak plas-
ma concentrations occur about 1–2 h after an oral dose
(80 mg), but vary greatly between individuals. The biological
half-life of propranolol is longer than would be anticipated
from its plasma half-life of about 3–6 h. It has a logarithm par-
tition coefﬁcient (logP) of 3.03 and short elimination half-life
of about 3 h (Zhao and singh, 1999), which makes it a suitable
candidate to be delivered transdermally at a controlled rate
(Aqil et al., 2005; Ahad et al., 2011). The enhancement of
hydrochloride salt of PP (PP–HCl) penetration by chemical
and physical enhancers across the skin in vitro has been stud-
ied (Hori et al., 1991). Recently, Ahad et al., 2011, studied the
effectiveness and mechanism(s) of percutaneous absorption of
PP–HCl across rat and human cadaver skin using seven novel
terpenes with reference to marker terpene 1,8-cineole (Ahad
et al., 2011). Terpenes are considered as safe absorption pro-
moters and they have been categorized as generally safe by
FDA (Aqil et al., 2007a; Akhtar et al., 2011). Furthermore,
they have ability to enhance the cutaneous permeation of lipo-
philic as well as hydrophilic actives (Hassan et al., 2010; Aqil
et al., 2007a,b). Ahad et al., claimed that amongst the terpenes,
1,4-cineole was found to be most effective enhancer for diffu-
sion of PP–HCl through rat skin (ER = 3.07) and human
cadaver skin (ER = 2.42) as compared to control. Fourier
transform infrared spectroscopy (FTIR) spectra and differen-
tial scanning calorimetry (DSC) thermogram of skin treated
with aforesaid terpenes indicated that permeation occurred
due to the disruption of lipid bilayers. No apparent skin irrita-
tion (erythema, edema) was observed on treatment of skin with
terpenes, the irritation was higher with the b-citronellene androse oxide. It was concluded that 1,4-cineole can be success-
fully used as potential permeation enhancer for PP–HCl (Ahad
et al., 2011).
Kunta et al., 1997 investigated the effect of menthol, limo-
nene, linalool and carvacrol on the percutaneous absorption of
PP–HCl across hairless mouse skin. Authors concluded that
alcohol terpenes are very effective in enhancing the transder-
mal transport of PP–HCl. In the case of linalool, the ﬂux val-
ues increase 6 to 7-fold at 5–10% terpene concentration,
whereas L-menthol provides a signiﬁcant enhancement in per-
cutaneous absorption at a concentration as low as 1%.
In another report, Zhao and Singh, investigated the mech-
anism(s) of percutaneous absorption enhancement of PP–HCl
across porcine epidermis by terpenes (e.g. menthone and limo-
nene) in combination with ethanol. Five percent menthone or
limonene in combination with ethanol (menthone/ethanol or
limonene/ethanol) signiﬁcantly enhanced the ﬂux of PP–HCl
across porcine epidermis in comparison to ethanol (control).
The partitioning of PP–HCl to the stratum corneum (SC) from
the SC/enhancer system was also signiﬁcantly greater than the
SC/control system. It was observed that the above terpenes
showed a decrease in the peak heights and areas for both
asymmetric and symmetric CAH stretching absorbance in
comparison with the untreated SC, indicating the SC lipids
extraction. Thus, an enhancement in the ﬂux of PP–HCl by
menthone/ethanol and limonene/ethanol is due to SC lipid
extraction, macroscopic barrier perturbation, and improve-
ment in the partitioning of the drug to the SC (Zhao and singh,
1999). Similar mechanism of action was also reported for the
terpenes such as (+)-borneol, (+)-camphor, and a-bisabolol
(Cui et al., 2011). It was described in the study that each of
(+)-borneol, (+)-camphor, and a-bisabolol signiﬁcantly in-
creased the transdermal ﬂux of PP–HCl through rat skin in
comparison to the control. The enhancement mechanism of
the terpenes is involved with disruption of the lipid bilayer
and increases the PP–HCl partitioning coefﬁcient to the SC
(Cui et al., 2011).
In 2005, Amnuaikit et al., developed ﬁlm formulations of
PP–HCl containing menthol, cineole and propylene glycol as
enhancers for transdermal use. In vitro skin permeation study
presented that cineole was found to be the most promising ter-
pene among the investigated enhancers which provided high
skin permeation rates (Amnuaikit et al., 2005).
It is reported in the literature that a variety of chemical per-
meation enhancers have been shown to increase percutaneous
absorption of both hydrophilic and hydrophobic drugs
(Williams and Barry, 2004; Hassan et al., 2010). In this regard,
a comparative study (Hori et al., 1992) was done for the percu-
taneous enhancement of a hydrophilic (PP–HCl) and a lipo-
philic drug (diazepam or indomethacin) by various enhancers
such as 1-nonanone, 1-nonalol and 1-decanol. It was found that
1-nonalol and 1-decanol signiﬁcantly enhance the PP–HCl ﬂux,
whereas the indomethacin or diazepam ﬂux is enhanced by
1-nonanone only. A rise in PP–HCl ﬂux by terpenes is reported
to be comparable to that observed with 1-nonalol (Hori et al.,
1992). The prodrug approach has also been employed to en-
hance the transdermal delivery of PP (Namdeo and Jain,
2002). An increase in PP–HCl ﬂux as high as 20- and 25-fold
can be achieved from two PP prodrugs namely hydrochloride
salts of PP stearate and PP palmitate respectively. Transdermal
administration of these prodrugs improves the bioavailability
of PP–HCl up to 7–8 times over the oral treatment.
Table 1 Research advances in systemic delivery of b-blockers via skin.
b-Blockers Characteristics Transdermal research Refs.
Nonselective b-blockers (b1 and b2)
PP MW= 259.34, BCS class = I
logP= 3, t1/2 = 4 h
Bioavailability = 23%, Well
absorbed following oral
administration at variable plasma
concentrations
Elastic liposomal of PP–HCl provided better transdermal ﬂux and higher entrapment eﬃciency Mishra et al. (2007)
n-Alkanes having chain lengths of between 7 and 16 promoted the ﬂux of PP–HCl Hori et al. (1991)
ER of 3.07 and 2.42 of PP were obtained when 1,4-cineole was used as penetration enhancer across
rat and cadaver skins, respectively
Ahad et al. (2011)
Permeability of PP was much higher from the hydrogel-based patches (methanol enhancer) than the
control patch across the mouse skin
Kunta et al. (1997)
Menthone (5%) in combination with ethanol signiﬁcantly increased the ﬂux of PHCL Zhao and singh (1999)
a-Bisabolol (5% w/v) increased the partition coeﬃcient of PHCl to the SC Cui et al. (2011)
PP transport across hairless mouse skin was improved signiﬁcantly in the presence of 4% (v/v) n-
nonane
Hori et al. (1992)
Developed a novel self-assembled pharmacogel for the enhanced transdermal delivery of PP–HCl Namdeo and Jain (2002)
Microdialysis technique was used as a tool for dermatopharmacokinetic studies Muller et al. (1995)
PP was delivered iontophoretically in the dermis of healthy human volunteers Stagni et al. (2000)
In vivo study in rabbits showed that a sustained therapeutic activity of PP was observed over a period
of 24 h after transdermal administration compared to oral administration
Rao et al. (2003)
TM MW= 432.50, BCS class = I
logP= 1.2, t1/2 = 2.5–5 h
Bioavailability = 75%
Water-activated, pH-controlled transdermal patches of TM were found to be well tolerated by the
hypertensive patients
Sutinen et al. (2000b)
In vivo study in rabbits showed that iontophoresis in combination with Azone can increase the
transdermal delivery of TM
Kanikkannan et al. (2000)
Plasma TM concentrations collected from the left antecubital vein were 2.4–10.7 times greater than
those from the right arm and had signiﬁcant correlations (rs = 0.55–0.76) with the parameters
indicating the extent of erythema developed where a patch containing TM was applied.
Kubota et al. (1991)
Rate of TM release was decreased when the control devices were placed on human cadaver skin Sutinen et al. (2000a)
In vivo study in humans indicated that steady-state plasma levels were achieved rapidly by
iontophoretic patches
Green (1996)
Total amount of TM transported up to 24 h was not signiﬁcantly diﬀerent among the diﬀerent
species studied
Kanikkannan et al. (2001)
Transdermal delivery of TM by electroporation through human skin was investigated Denet and Pre´at (2003)
Laurate sugar fatty acid ester with shorter fatty acid chain length and higher HLB value signiﬁcantly
increased the amount of TM liberated from the patch (99%) and its permeation across rat skin
(86%)
El-Laithy (2009)
Lauryl chloride was found to be the most eﬀective penetration enhancer for transdermal delivery of
TM
Soni and Dixit (1994)
BPL MW= 271.78, BCS class = II
logP= 2.9, t1/2 = 2–4 h,
Bioavailability = 10%
Used isopropyl myristate and N-methyl-2-pyrrolidone as enhancer and in vitro penetration of BPL
obtained 3.6 times higher ﬂux compared with that without enhancers
Ogiso et al. (2001)
Hydroxy propyl b-cyclodextrin and partially methylated b-cyclodextrin were used as penetration
enhancers for BPL
Babu and Pandit (2004)
Reservoir-type TTS of BPL was developed and penetration enhancers increased the skin permeation
of BPL at 4–5 times higher levels than the desired target delivery rate
Babu and Pandit (2005a)
2-Pyrrolidone and 1-methyl-2-pyrrolidone (5% w/v) increased permeation of BPL by 3.8- and 2.4-
fold respectively through the rat skin
Babu and Pandit (2005b)
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Selective b-1 blockers
AT MW= 266.33, BCS class = III
logP= 0.5, t1/2 = 6–7 h,
Bioavailability = 50%
Used polyoxyethyene-2-oleyl ester as penetration enhancer for enhanced AT tra sdermal delivery Shin and Choi (2003)
Developed TTS using blends of diﬀerent polymeric combinations such as HPMC VP and carbopol
for transdermal delivery AT
Anitha et al. (2011)
Modiﬁed xanthan ﬁlms were applied as a matrix system for the transdermal del ery of AT Mundargi et al. (2007a,b)
Permeation via cadaver skin showed about 27% reduction in the amount of AT s compared to rat
abdominal skin
Agrawal and Munjal (2007)
Developed a matrix-type TTS with diﬀerent concentrations of hydrophobic poly ers like E-RL100
and E-RS100 by the solvent evaporation technique
Baria and Patel (2011)
Polyoxyethylene 2-oleyl ether showed the best enhancement among others enha ers used such as
glycols, fatty acids and non-ionic surfactants
Cho and Shin (2004)
In vivo study in rabbits showed that bioavailability of AT was increased by 46% from an EVA
matrix system
Shin and Choi (2003)
MP MW= 267.36, BCS class = I
logP= 1.6, t1/2 = 3–7 h,
Bioavailability = 50%
Optimized TTS comprising HPMC E50 + EC (3:2), with enhancer DMSO showe 70% drug release
after 12 h
Thakare et al. (2012)
Improved in vitro drug release and skin permeation of monolithic matrix system of MP Aqil et al. (2003)
Signiﬁcant reduction in mean blood pressure was achieved in methyl prednisolo e-induced
hypertensive rats on treatment with the TTS of MP
Aqil et al. (2004)
n-Decylmethyl sulfoxide was found to enhance skin permeation rate of MP thro gh the human
cadaver skin at a loading dose of 5% (w/w)
Ghosh et al. (1992)
3-Fold improvement in bioavailability of MP was observed with the TTS Aqil et al., 2007a,b
Used Easyjet Plus (Equibio) electroporating equipment for the permeation en ncement of MP
across hairless rat skin
Vanbever et al. (1994)
Signiﬁcant enhancement of MP across full thickness hairless rat skin was observe in comparison to
diﬀusion through untreated skin
Vanbever et al. (1996)
BSP MW= 325.44, BCS class = I
logP= 2.2, t1/2 = 9–12 h,
Bioavailability = 80%,
Approximately 50% of the dose
is metabolized by CYP3A4
BSP-maleate was found the most promising candidate for long-acting transderm l patches among
the diﬀerent ion-pair complexes prepared such as BSP maleate, BSP tartarate, BS besilate, and BSP
fumarate
Song et al. (2012)
Azone can be used as a good penetration enhancer for BSP Dinakar et al. (2010)
Developed a novel TTS containing isosorbide dinitrate with BSP. The bioavaila ility of 33.6% for
isosorbide dinitrate, and 31.3% for BPL was observed on transdermal delivery rabbits
Zhao et al. (2007)
(continued on next page)
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Table 1 (continued)
Mixed b-blockers (has additional a-blocking activity)
CVD MW: 406.47, BCS class = II
logP= 2.2, t1/2 = 7–10 h,
Bioavailability = 25–35%,
undergoes extensive ﬁrst pass
In vivo studies concluded that the CVD transdermal patches provided steady-state asma
concentrations with minimal ﬂuctuations and improved bioavailability (71%) in rat
Ubaidulla et al. (2007)
CVD matrix TTS composed of a 4:1 ratio of HPMC and E-RL100 showed both m imum drug
release (12.31 mg) and permeation (2987.67 lg/cm2) in 24 h across the rat skin
Gannu et al. (2008a)
The steady-state plasma level and improvement in bioavailability (72%) of CVD in ra was obtained
following transdermal application
Kshirsagar et al. (2012)
Resulted in sustained release of CVD transdermal patches containing glycyrrhizin–ch osan mixture
which was able to control the hypertension in DOXA induced hypertensive rats thr gh 28 h
Sapra et al. (2008)
Black cumin oil (5%) was found the best permeation enhancer amongst several enhan rs tested such
as tulsi (basil) oil, eucalyptus oil, clove oil, OA and Tween 80
Amin et al. (2008)
Diﬀerent matrix-type transdermal patches were formulated to study the eﬀect of po mers on
transdermal release
Agrawal and Aggarwal (2010)
Resulted in sustained release of CVD transdermal patches containing soybean extra -chitosan
mixture which was able to control the hypertension in DOXA induced hypertensive ra through 24 h
Sapra et al. (2009a)
Resulted in sustained release of CVD transdermal patches containing Asparagus rac osus extract-
chitosan mixture which was able to control hypertension in DOXA induced hyperte sive rats
through 36 h
Sapra et al. (2009b)
Nanoemulsion consisted of OA: isopropyl myristate (1:1, 6%), Tween 80 (22.5%), T anscutol-P
(22.5%), and distilled water showed higher permeation rate of CVD via rat skin
Dixit et al. (2008)
CVD ﬂux in the presence of camphor, limonene, Transcutol, carvone, Labrasol, an menthol
solution (5% w/v), were 9.7, 7.6, 7.6, 6.3, 4.7, and 2.3 times higher, respectively, tha that observed
with control across porcine skin
Gannu et al. (2008b)
LHCL MW= 364.87, BCS class = I
logP= 2.7, t1/2 = 6–8 h,
Bioavailability = 100%, Almost
completely absorbed from the
gastrointestinal tract, undergoes
signiﬁcant ﬁrst pass
Matrix type TTS comprised of LHCL (36%), enhancer DMSO (10–12%) and plast izer PEG 400
(2.5–7.5%) in methanol-acetone solvent system was developed for transdermal appl tions
Aqil et al. (2005)
DMSO (10% v/v) was found to be the most eﬀective enhancer for LHCL via the d mal route Zafar et al. (2010)
TTS comprised of E-EPO/E-RL100 and Plasdone S 630 as polymers and LHCL was vestigated for
the therapy of hypertension
Mittal et al. (2009)
AT: atenolol; BPL: bupranolol; BCS: biopharmaceutical classiﬁcation system; BPS: bisoprolol; CVD: carvedilol; DMSO: dimethyl s foxide; DOXA: deoxycorticosterone acetate; ER:
enhancement ratio; E: eudragit; HPMC: hydroxy propyl methyl cellulose; LHCL: labetalol hydrochloride; logP: logarithm partition coefﬁcien MP: metoprolol; MW: molecular weight; OA: oleic
acid; PP: propranolol; PVP: polyvinyl pyrolidone; t1/2: half-life; TM: timolol maleate; TTS: transdermal therapeutic system.
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Systemic delivery of b-blockers via transdermal route for hypertension 593Skin microdialysis is another technique which permits to
measure the kinetics of drug appearance in the dermis under
the site of application of drugs in vivo and in humans
(Anderson et al., 1991; Groth, 1996; Muller et al., 1995). Thus,
skin microdialysis technique was employed to characterize and
quantify the dermatopharmacokinetics of iontophoretically
delivered PP–HCl in the dermis of healthy human volunteers.
Microdialysis probes were inserted in the subject’s forearm
skin and an iontophoresis device was installed above them.
Constant current was applied for two periods of 1 h each sep-
arated by a 1 h interval. Dialysate samples were collected every
6 min for 4.4 h and analyzed. It was observed that the skin
microdialysis technique was well tolerated and this study dem-
onstrates that intradermal microdialysis is suitable to examine
the dermato pharmacokinetics of iontophoretically delivered
drugs in the dermis of human subjects. Elimination was well
characterized. Quantiﬁcation of the absorption process by
AUC showed a high inter- and intra-subject variability sug-
gesting that more studies are needed to understand whether
such variability is due to variation in microdialysis recovery,
in iontophoretic delivery, or in dermis clearance (Stagni
et al., 2000). In another study, the antihypertensive activity
and pharmacokinetic performance of PP–HCl in rabbits fol-
lowing transdermal administration was compared with that
of oral administration. In contrast to oral delivery, a sustained
therapeutic activity was observed over a period of 24 h after
transdermal administration and 5 to 6-fold increase in relative
bioavailability of PP–HCl was observed after transdermal
administration in comparison to oral administration. This
may be due to the avoidance of ﬁrst pass effect of PP–HCl
and the sustained therapeutic activity was due to the controlled
release of drug into systemic circulation following transdermal
administration (Rao et al., 2003). In 2000, Verma and Iyer also
reported slow and controlled release of PP–HCl from poly-
meric matrix type transdermal ﬁlms prepared with different
grades and ratios of Eudragit (E) (Verma and Iyer, 2000).
In another study, polymeric ﬁlms containing PP–HCl were
formulated using different ratios of ethyl cellulose (EC), poly-
vinyl pyrrolidone (PVP) by mercury substrate method. It was
observed that the release rate of PP–HCl increased linearly
with increasing drug concentration and PVP fraction in the
ﬁlm, but was found to be independent of ﬁlm thickness. The
increase in release rate may be due to leaching of hydrophilic
fraction of the ﬁlm former, which resulted in the formation
of pores. It was also observed that the release of PP–HCl from
the ﬁlms followed the diffusion-controlled model at low drug
concentration. A burst effect was observed initially, however,
at high drug loading level, which may be due to rapid dissolu-
tion of the surface drug followed by the diffusion of the drug
through the polymer network in the ﬁlm. The transdermal ﬂux
values were also added with increase of initial drug concentra-
tion in the ﬁlm, and also with the PVP content. It was
suggested that prepared ﬁlm should be selected for the devel-
opment of TTS using a suitable adhesive layer and backing
membrane for potential therapeutic applications (Rao et al.,
2000). In another report, release of PP–HCl from hydroxy pro-
pyl methyl cellulose (HPMC) matrices without adhesive coat-
ing was found to be fast. Release from these matrices
became more regular (reduction of the burst effect) and slow
when they are coated with a 12 mm thick Ucecryl layer.
Release from different polyisobutylene matrices was found
too slow to be suitable as TTS for PP–HCl. Amongst theinvestigated polymers the best release modulation was ob-
tained from Ucecryl matrices (Guyot and Fawaz, 2000). In an-
other investigation, formulations with the highest proportion
of PVP shows faster release of PP–HCl over a day’s span
whereas increasing the proportion of EC produces a prolonged
regimen of sustained drug delivery through the transdermal
route for a period of more than a day. It was demonstrated
that the fabricated matrix ﬁlms have the potential to prolong
the release of PP–HCl (Dey et al., 2007). The PP–HCl release
was regulated by the use of cross-linking agent glutaraldehyde
in transdermal membrane prepared by chitosan a natural poly-
mer. Chitosan gel was used as the drug reservoir. The ability of
these devices to deliver the drug while supported on rabbit pin-
na skin was tested by conducting in vitro studies in modiﬁed
Franz diffusion cells. The drug release proﬁles showed that
the PP–HCl delivery is completely controlled by the devices.
The rate of PP–HCl release was found to be dependent on
the type of membrane used. It has been proved that natural
polymer chitosan can be used successfully for the fabrication
of transdermal devices. The drug release can be easily tailored
by changing the permeability of the membrane by chemical
modiﬁcations, like cross-linking or by changing the area of
the devices. With the usage of natural polymers such as chito-
san for the fabrication of TTS, most of the device-associated
adverse skin reactions can be minimized (Thacharodi and
Rao, 1995). Rate of PP–HCl release from the pH-controlled,
water-activated reservoir devices was also controlled over a
700-fold range by using suitable buffers in the device core
(Sutinen et al., 1989, 1990, 2000a).
In another investigation, reservoir-type transdermal enan-
tioselective-controlled delivery system for racemic PP–HCl
using a molecularly imprinted polymer composite membrane
was examined. The chitosan gel allowed excellent selectivity
for delivery of the (S)-PP–HCl enantiomer, whilst the more
rheologically structured poloxamer gel formulation provided
no selective release of (S)-PP–HCl. The chitosan gel exhibited
high ﬂux and had the ability for enantioselective delivery of
(S)-PP–HCl across excised rat skin. The reservoir patch for
enantiomer-controlled delivery of PP–HCl was therefore fabri-
cated by incorporating the chitosan gel formulation containing
racemic PP–HCl into the molecularly imprinted polymer com-
posite membrane laminated backing. These patch devices were
shown to exhibit the signiﬁcant stereoselectivity uptake of PP–
HCl. (S)-PP–HCl enantiomer plasma concentration proﬁles
for the transdermal patch in the in vivo study were comparable
to data for the gel formulations that were applied directly to
skin, and containing a single S-enantiomer of PP–HCl. The
results demonstrate that the transdermal patch based on the
molecularly imprinted polymer composite membrane-
controlled release system may have potential in the enantiose-
lective-controlled delivery of the S-isomer of racemic PP–HCl
(Suedee et al., 2008).
Ultradeformable lipid vesicles i.e. elastic liposomes are
specially optimized vesicles, which can respond to an external
stress by rapid and energetically inexpensive shape transforma-
tions. Elastic liposomes differ from conventional niosomes and
liposomes by their characteristic ﬂuid membrane with high
elasticity (Ahad et al., 2012; Ahad et al., 2013a,b). The elastic-
ity of these vesicles is attributed to the simultaneous presence
of different stabilizing (phospholipids) and destabilizing
(surfactant) molecules and their tendency to redistribute in
bilayers. Such highly deformable vesicles can thus be used to
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skin. Elastic liposomes were prepared by Mishra et al., 2007
for enhanced PP–HCl transdermal delivery. Elastic liposomes
loaded with PP–HCl were prepared by conventional rotary
evaporation method. It was observed that the elastic liposome
of PP–HCl provides better transdermal ﬂux, higher entrap-
ment efﬁciency, ability as a self-penetration enhancer and
effectiveness of transdermal delivery as compared to tradi-
tional liposomes (Mishra et al., 2007). The lower penetration
ability that is associated with the use of vesicular carriers such
as liposomes and niosomes can be overcome by entrapment of
the drugs in the elastic liposomes.
2.2. Timolol
TM is a hydrophilic potent b-adrenoceptor blocking agent that
is used to treat hypertension, angina pectoris and myocardial
infarction. It possesses a relatively high degree of lipid solubil-
ity with a logarithm partition coefﬁcient (logP) of 1.2. TM is
rapidly absorbed following oral ingestion and metabolized
up to 80% in liver with a mean half-life of 2.0–2.5 h and pres-
ent oral bioavailability of about 75%, thus necessitating fre-
quent administration of doses to maintain therapeutic drug
level, hence transdermal delivery could be a potential alterna-
tive to oral delivery of TM (Kubota et al., 1991; Kanikkannan
et al., 2000, 2001; Sutinen et al., 2000a). In 1994, Soni and Dix-
it used dimethyl sulfoxide (DMSO), oleic acid (OA) and lauryl
chloride to enhance the permeability of TM via human cada-
ver skin. The authors claimed that lauryl chloride was found
to be the most effective enhancer to accentuate transdermal
delivery of TM, followed by DMSO and OA (Soni and Dixit,
1994).
Consequently, water-activated, pH-controlled devices were
investigated for the transdermal delivery of TM. It was ob-
served that TM release from unbuffered devices was negligible,
while there was a pronounced effect of pH-adjusting agents on
TM release e.g., TM release from the device was found to be
3150 times greater in presence of a Tris buffer (Sutinen
et al., 2000a). In another report (Sutinen et al., 2000b)
water-activated, pH-controlled transdermal patches of TM
were found to be well tolerated by the subjects, edema raised
by the patches was negligible and erythema was conﬁned only
to the area where the TM patch was applied. It was also men-
tioned that the TM–Tris buffer patch was releasing TM faster
than the TM–disodium phosphate patch (Sutinen et al.,
2000b). It was concluded that by application of water-acti-
vated and pH-controlled devices, steady-state plasma concen-
trations and the duration of patch activity in vivo can be
controlled by selecting suitable buffers in the device core.
It is reported in the literature that the skin of infants was
found to be more permeable to drugs than that of adults
and passive diffusion of drugs across the skin of common lab-
oratory animals (e.g. rat, rabbit and mouse) was found to be
higher than human skin (Kanikkannan et al., 2001; Wester
and Maibach, 1987). It was also mentioned that percutaneous
absorption through pig and monkey (squirrel and rhesus) was
found to be more closely related to that of human (Kanikkannan
et al., 2001; Wester and Maibach, 1987). In this quest, a study
was performed to investigate the effect of species variation of
the animals (rat, rabbit, mouse, guinea pig and human) on
the transdermal iontophoretic transport of TM. Iontophoresishas been demonstrated to be a safe means of delivering pep-
tides and other molecules in a noninvasive and controllable
fashion (Kanikkannan et al., 2001; Singh and Singh, 1993;
Green, 1996). Further, the amount of drug transported by ion-
tophoresis is proportional to the current applied, it is possible
to deliver the drug in a controlled manner using prepro-
grammed delivery rates (Kanikkannan et al., 2001; Sage,
1993). The author claimed that the iontophoretic transport
of TM across the skins obtained from the rats of different
age groups was found to be similar. It was suggested that
the age of the animal (Wistar rats: 1–8 months) did not appear
to inﬂuence the transdermal iontophoretic transport of TM
(Kanikkannan et al., 2001). In another study, it was observed
that the application of skin electroporation strongly promotes
the transdermal delivery of TM in vitro compared to passive
diffusion and the therapeutic ﬂuxes of TM (>50 lg/cm2/h)
through human SC were achieved with the electrical protocols
used. It was concluded that the choice of the electrical param-
eters (voltage, duration and number of pulses) allows a control
of the quantity of drug transported through the skin (Denet
and Pre´at, 2003).
In 2009, El-Laithy, prepared a matrix type controlled trans-
dermal patch containing TM and sugar fatty acid ester as pen-
etration enhancer. It was observed that among different acid
esters tried, laurate acid ester with shorter fatty acid chain
length and higher hydrophilic lipophilic balance value signiﬁ-
cantly increased the amount of TM released from the patch
(99%) and its permeation across rat skin (86%). The total drug
permeation and ﬂux values were approximately 5-fold greater
compared to acid ester free patch. The developed patch was
well tolerated by all the subjects with only moderate skin irri-
tation, which was recovered in 24 h after patch removal. The
reports are very promoting and offer an alternative overture
to maintain a higher, prolonged and controlled blood level
proﬁle of the drug over 18–24 h (El-Laithy, 2009).
2.3. Bupranolol
BPL is a potent nonselective b-blocking agent (Tsukahara
et al., 1986). BPL was quickly and completely absorbed from
the gut with less than 10% oral bioavailability. Upon oral
administration it undergoes an extra-ordinary ﬁrst-pass metab-
olism (>90%). It has a logP value of 2.9 and is rapidly elim-
inated with a biological half-life of 1.5–2.0 h. This demands
multiple ingestion of a heavy oral dose (100–400 mg/day) in
divided doses, which in turn results in undesirable local and
systemic side effects (Waller et al., 1982; Wellstein et al.,
1986). These properties of BPL make it well suited for TTS
development. In previous reports, isopropyl myristate and
N-methyl-pyrrolidone have been used as absorption promoters
for BPL. N-methyl-pyrrolidone provides a 3.6-times higher
BPL ﬂux than passive diffusion (Ogiso et al., 2001). Isopropyl
myristate and N-methyl-pyrrolidone enhance the penetration
by increasing the solubility of the permeant into SC.
Babu and Pandit, 2004 reported a 3.8- and 4.6-fold
enhancement in BPL ﬂux over the control through rat skin
by using hydroxy propyl b-cyclodextrin and partially methyl-
ated b-cyclodextrin (PMbCD) in 1% aqueous suspension of
BPL, cyclodextrins increase the aqueous solubility of the drug
and reduce the barrier function of the skin (Babu and Pandit,
2004). The release rate of BPL from HPMC, hydroxy propyl
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than gel reservoirs of carboxymethyl cellulose, sodium car-
boxymethyl cellulose and sodium alginate. Permeation rates
of the devices containing 5% (w/v) pyrrolidone or 1-methyl-
2-pyrrolidone were about 3- and 1.5-fold higher than the
control. Pyrrolidone was found to be a better penetration
enhancer for BPL than 1-methyl-2-pyrrolidone. The perme-
ation rates of devices containing PMbCD and PMbCD-BPL
complex were about 2.5- and 1.4-fold higher than the control.
It was suggested that reservoir-type TTS of BPL was devel-
oped and penetration enhancers increased the skin permeation
of BPL at 4–5 times higher levels than the desired target deliv-
ery rate (Babu and Pandit, 2005a). In another study, the effect
of different penetration enhancers viz. 2-Pyrrolidone, 1-
methyl-2-pyrrolidone, and propylene glycol on the permeation
of BPL across the rat skin was investigated. Menthol at differ-
ent concentrations in isopropanol-water (6:4) mixture was also
used as an enhancer wherein BPL at 0.4% w/v was completely
solubilized. Skin pretreatment studies were carried out with all
the above enhancers to understand their role in the penetration
enhancement effect. 2-Pyrrolidone and 1-methyl-2-pyrrolidone
at 5% w/v concentrations increased the permeation of BPL by
3.8- and 2.4-fold, respectively, over the control. Propylene gly-
col at 10% and 30 w/v concentrations increased the ﬂux of
BPL by 2.5- and 5.0-fold, respectively, as compared to the con-
trol. Menthol at 2% w/v concentration increased the ﬂux of
BPL by 3.8-fold and a further increase in menthol concentra-
tion signiﬁcantly decreased the ﬂux of BPL. Overall, pyrroli-
dones and menthol at low concentrations (5% w/v or less)
and propylene glycol at 30% w/v concentration were found
to be effective penetration enhancers for the transdermal deliv-
ery of BPL (Babu and Pandit, 2005b).
3. Selective b-1 blockers
3.1. Atenolol
AT belongs to the class of b-1 selective adrenoceptor antago-
nists. It has been used for the treatment of hypertension and sta-
ble angina either alone or with other antihypertensive drugs like
thiazide diuretics (Salvetti and Ghiadoni, 2006; Lim, 2007). AT
is a highly soluble low permeable drug (BCS class 3) with a logP
value of 0.5. Due to incomplete intestinal absorption, the
systemic bioavailability is about 50–60% in the human
(Stoschitzky et al., 1993). The peak plasma concentrations
occur about 2–4 h after an oral dose of 50–100 mg. It is reported
that in the case of oral administration of AT, it can induce side
effects such as diarrhea, nausea, mesenteric arterial thrombosis,
ischemic colitis and dry mouth (Vaithiyalingam et al., 2001;
Mundargi et al., 2007a). AT is reported to be subjected to exten-
sive hepatic ﬁrst-pass metabolism following the oral administra-
tion and has a short biological half-life of 6–7 h (Singh et al.,
2006; Mundargi et al., 2007b). Therefore, to maintain proper
blood levels for a long time and to mitigate the adverse effect
associated with frequent oral administration of AT, develop-
ment of TTS of AT is very important (Kim and Shin, 2004;
Cho and Shin, 2004). Recently, a TTS containing AT &Gliben-
clamide was prepared for hypertension associated with diabetes
using blends of different polymeric combinations such as
HPMC, PVP and carbopol. The prepared formulation showed
zero order drug release pattern by diffusion mechanism of thenon ﬁckian type. It was concluded that prepared formulation
showed prolonged zero order release, reduced frequency of
administration, greater therapeutic effect, overcomes the side
effects, simpliﬁes the treatment regimen and thus may improve
patient compliance (Anitha et al., 2011). In another study, mod-
iﬁed xanthan ﬁlms as a matrix system for transdermal delivery
of AT were prepared. All the thin ﬁlms prepared were slightly
opaque, smooth, ﬂexible, and permeable to water vapor, show-
ing their permeability characteristics suitable for transdermal
studies. The skin irritation test was done in mice and it was ob-
served that both placebo and drug loaded ﬁlms produced negli-
gible erythema and edema compared to formalin (standard
irritant). The in vitro drug release studies were performed using
a Keshary–Chien diffusion cell and the mechanism of drug re-
lease was found to be Fickian diffusion (Mundargi et al.,
2007b). In 2007, Agrawal and Munjal prepared a matrix type
transdermal patches comprising AT and MP-tartrate using
1,8-cineole as the permeation enhancer. The polymers selected
were PVP, cellulose acetate phthalate, HPMC and EC. Backing
membrane was prepared bywrapping an aluminum foil over the
Teﬂon mold. In vitro permeation studies were performed using
rat abdominal skin as the permeating membrane in the Kesh-
ary-Chien cell. The maximum release was obtained at 48 h
(85% and 44% of AT and MP-tartrate, respectively). The per-
meation studies via cadaver skin showed about 27% reduction
in the amount of drug release compared to the skin permeation
study performed on rat abdominal skin. It was observed that
the physical appearance of the patches and the effect on ageing
showed that the patches need to be stored in properly sealed air
tight packing to keep them protected from extremes of moisture
that may alter their appearance (Selvam et al., 2010; Agrawal
and Munjal, 2007). In another investigation, feasibility of OA
for the delivery of AT via rat skin was examined, a matrix-type
TTS containing AT and OA using different concentrations of
hydrophobic polymers like E-RL100 and E-RS100 was pre-
pared by the solvent evaporation technique. Formulation pre-
pared with E-RL100 polymer containing OA showed good
physical stability and produced maximum transdermal ﬂux
via rat skin as compared with all other formulations (Baria
and Patel, 2011). In another report, OA is reported as the best
penetration enhancer for AT amongst a pool of fatty acids
including linoleic acid, caprylic acid and lauric acid (Cho and
Shin, 2004). It was suggested that OA creates pores on the sur-
face of corneocytes, indicating transcellular permeation of ac-
tive as the possible mechanism of penetration enhancement
(Touitou et al., 2002). Shin et al. used polyoxyethyene-2-oleyl
ester and tributyl citrate as a penetration enhancer and plasticis-
er, respectively, to form an ethylene–vinyl acetate matrix system
for an enhanced bioavailability of AT in rabbits (Shin andChoi,
2003). They reported a 46% increase in bioavailability of AT in
the enhancer group over the control group (with no enhancer).
An insigniﬁcant increase in the Cmax in the enhancer group was
observed, although Tmax decreased signiﬁcantly in the enhancer
group. Sustained release and constant blood concentration with
minimal ﬂuctuation is possible from the above ethylene–vinyl
acetate – AT matrix.
3.2. Metoprolol
MP is a cardio selective b-blocker. It is used in the manage-
ment of hypertension, angina pectoris, cardiac arrhythmias
596 A. Ahad et al.and myocardial infarction. It is almost completely absorbed
after oral administration, although the systemic bioavailability
varies (40% to 50%) widely owing to extensive presystemic
metabolism. It is similar to AT in its moderate lipid solubility
with logP 1.6. The plasma half life is about 4 h, which makes
frequent dosing necessary to maintain the therapeutic blood
levels of the drug for a long term treatment (Corbo et al.,
1990; Bharkatiya et al., 2010). The transdermal route of
administration is capable of avoiding the hepatic ﬁrst pass ef-
fect, thus achieving higher systemic bioavailability of drugs.
Recently, matrix type transdermal ﬁlms of succinate salt of
MP were prepared using different polymers such as EC,
HPMC (E15, E50) and PVP in varied ratios. All formulations
carried DMSO (5%) as penetration enhancer and propylene
glycol (30%) as plasticizer in chloroform and ethanol as sol-
vent system. The formulation with a combination of polymers
HPMC E50 + EC with DMSO emerged to be the ideal formu-
lation and showed 70% drug release after 12 h (Thakare et al.,
2012).
In 2003, Aqil et al., developed a four monolithic matrix sys-
tem of MP (used in tartrate form), which differed in the ratio
of matrix-forming polymers. Formulations MT-1, MT-2, MT-3
and MT-4 were composed of E-RL100 and PVP K-30 with the
following ratios: 2:8, 4:6, 6:4 and 8:2, respectively. On the basis
of in vitro drug release and skin permeation performance, for-
mulation MT-4 was found to be better than the other three
formulations and it was selected as the optimized formulation.
It was concluded that MP could be administered transdermally
through the matrix type TTS (Aqil et al., 2003).
In another study, Aqil et al., 2004 prepared four MP (used
in tartrate form) formulations using E-RL100 and Polyvinyl
alcohol (PVA) in different ratios. Formulations M-1, M-2,
M-3, and M-4 were composed of E-RL100 and PVA with
the following ratios: 2:8, 4:6, 6:4, and 8:2, respectively. All
the four formulations carried 10% (w/w) of MP, 5% (w/w)
of dibutyl phthalate, and 5% (w/w) of menthol in dichloro-
methane: isopropyl alcohol (80:20 v/v). The cumulative
amount of drug permeated from the four formulations was
59.72%, 66.52%, 77.36%, and 90.38% respectively. Formula-
tion M-4 was found to be better than the other three formula-
tions and it was selected as the optimized formulation. The
formulation was found to be free of any skin irritation as sug-
gested by a skin irritation score of 1.16 (<2.00) under the Dra-
ize score test. Signiﬁcant reduction in mean blood pressure was
achieved in experimental hypertensive rats on treatment with
the TTS. The authors concluded that MP developed formula-
tion holds promise to be a viable option for effective and con-
trolled management of hypertension for 48 h (Aqil et al.,
2004). Ghosh et al. explored the feasibility of transdermal
administration of MP by investigating its permeation across
hairless mouse and human cadaver skin using N-decyl methy
sulfoxide as an enhancer. The authors claimed that MP
permeated through the mouse and human cadaver skin in
therapeutically effective amounts from a polyacrylate patch
bearing N-decyl methy sulfoxide as an enhancer (5% w/w)
with no signiﬁcant lag time (Ghosh et al., 1992).
An open-label, balanced randomized, two-treatment, two-
period crossover study was done (Aqil et al., 2007b) to
compare the bioavailability of tartrate form of MP from a
TTS with that from a conventional marketed tablet in healthy
human volunteers. Volunteers were randomized to have a TTS
applied to their chest for 48 h or to receive a 100 mgconventional marketed tablet of MP in period I. In period
II, the volunteers received the other dosage form. A 3-fold
improvement in bioavailability was observed with the TTS
form over oral therapy. Plasma MP concentrations drop shar-
ply to therapeutically ineffective concentrations as early as 8 h
following oral administration. Finally it was concluded that
the developed TTS conforms to the intended objective of
two-day management of hypertension with the application of
a single patch, avoiding the inconvenience of frequent admin-
istration and thus improving patient compliance (Aqil et al.,
2007b).
One of the most recent techniques in transdermal drug
delivery is electroporation. This is a reversible phenomenon
in which a lipid bilayer that is exposed to high-intensity electric
ﬁeld pulses is temporarily modiﬁed by the creation of transient
pores, thus allowing the enhanced permeation of actives.
Vanbever et al. (1994) used Easyjet Plus (Equibio) electropo-
rating equipment for the permeation enhancement ofMP across
hairless rat skin. The authors claimed signiﬁcant enhancement
ofMPacross full thickness hairless rat skin in comparison to dif-
fusion throughuntreated skin.An increase in the number of twin
pulses (300 V for 3 ms, followed after 1 s by 100 V for 620 ms)
raises drug transport. Single pulse (100 V, 620 ms) is found to
be as effective as twin-pulse application (2200, 1100 or 300 V
for 3 ms; followed after 1 s by 100 V for 620 ms). It was sug-
gested that diffusion factors like pulse voltage, pulse number
and pulse duration control the quantity of drug delivered
(Vanbever et al., 1996; Prausnitz, 1999).3.3. Bisoprolol
BSP is a highly selective b1-adrenoceptor antagonist. BSP has
a long duration of action, both systolic and diastolic blood
pressure are reduced by BSP (by up to about 20%, respec-
tively, in healthy subjects and in patients with mild to moder-
ate essential hypertension) as well as mycocardial oxygen
demand (by up to 34%) (Kanikkannan et al., 2001; Costello
and Jeske, 1995; Zhao et al., 2007). The absolute bioavailabil-
ity after a 10 mg oral dose of BSP fumarate is about 80%.
Peak plasma concentrations occur within 2–4 h of dosing with
5–20 mg, and mean peak values range from 16 ng/mL at 5 mg
to 70 ng/mL at 20 mg. BSP has a biological half life of 10–12 h
and oral bioavailability (90%). It has logP of 2.3 in n-octanol/
phosphate buffer system (Leopold et al., 1986). The key to
achieve long-acting effects for transdermal patches is to con-
trol the drug skin-permeating rate in a moderate range, that
is, neither too high and leading to a relatively high blood con-
centration nor too low to obtain the therapeutic effect. To
date, the most common strategies of controlling ﬂux include
the use of release controlling membranes and suitable adhesive
matrixes. In this aspect, recently a novel simple method of con-
trolling BSP ﬂux by ion-pair was initiated. Different ion-pair
complexes including BSP-maleate, BSP-tartarate, BSP-besi-
late, and BSP-fumarate were prepared and their ﬂuxes through
rabbit abdominal skin were determined separately in vitro. It
was observed that compared to free BSP, all BSP ion-pair
complexes displayed lower and controllable ﬂux. After form-
ing ion-pair complexes, the capability of BSP to penetrate
through skin was weakened due to the lowered logP and in-
creased molecule weight. It was demonstrated that the ﬂux
of BSP could be controlled by ion-pair strategy. Among all
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candidate for long-acting transdermal patches (Song et al.,
2012). While in another study, azone was used to enhance
transdermal ﬂux of BSP (used as fumarate salt) and about
98.3% BSP release was observed across the transdermal patch
prepared using PVP, PVA (Dinakar et al., 2010).
The combination therapy of nitrate and selective b-adreno-
ceptor antagonist has shown beneﬁts for the treatment of
hypertension and heart disease than either drug alone. In this
aspect, the blood pressure lowering effect and pharmacokinet-
ics of a novel transdermal patch incorporating isosorbide dini-
trate with BSP were investigated (Zhao et al., 2007). The
in vitro transdermal penetration of both isosorbide dinitrate
and BSP from the patches showed a zero-order process. After
transdermal administration at single dose or multiple doses,
the synergistic blood pressure lowering effect was conﬁrmed
in spontaneously hypertensive rats. The effect of each patch
lasts for 3 days, and increased with the total dose of two drugs,
showing a dose dependant manner. After transdermal admin-
istration in rabbits, Cmax of both drugs was signiﬁcantly re-
duced while the areas under the plasma concentration–time
curve, and mean residence times were evidently increased
and extended, respectively. As a patient-friendly, convenient,
and multi-day dosing therapeutic system, the transdermal
patches incorporating isosorbide dinitrate and BSP could be
promising for the prevention and treatment of hypertension
(Zhao et al., 2007).4. Mixed b-blockers (has additional a-blocking activity)
4.1. Carvedilol
CVD is a non-selective b-blocker. It blocks b-1 and b-2 adren-
ergic receptors as well as the a-1 adrenergic receptors. It is the
most widely prescribed drug in the long term treatment of
hypertension. It is clinically indicated not only in the manage-
ment of hypertension, but for myocardial infarction and con-
gestive heart failure too. CVD is rapidly absorbed following
oral administration, despite being well-absorbed, its oral bio-
availability in human is about 20%, due to a signiﬁcant degree
of ﬁrst-pass metabolism. CVD has a low molecular weight
(406.5), a favorable logP (4.115), with a short plasma half-life
of 6 h (Chakraborty et al., 2009; Wen et al., 2010; Singh et al.,
2013). Long term therapy of hypertension by CVD oral admin-
istration may result in poor patient compliance because of low
oral bioavailability in humans, leading to increased frequency
of administration (Morgan, 1994; Hokama et al., 1999; Singh
et al., 2013). Thus, CVD was found to be a good drug candi-
date for developing a transdermal system because of its phys-
icochemical proﬁle.
Ubaidulla et al., 2007 developed a matrix-type TTS con-
taining CVD with different ratios of hydrophilic and hydro-
phobic polymeric combinations such as (a) EC and PVP,
and (b) E-RL100 and E-RS100 by the solvent evaporation
technique. The bioavailability studies in rats indicated that
the CVD transdermal patches provided steady-state plasma
concentrations with minimal ﬂuctuations and improved bio-
availability in comparison with oral administration. The anti-
hypertensive activity of the patches in comparison with that
of oral CVD revealed that the patches signiﬁcantly controlled
the hypertension in methyl prednisolone acetate-inducedhypertensive rats (Ubaidulla et al., 2007). Monolithic matrix-
type TTS for CVD were prepared using a ﬁlm casting tech-
nique involving different ratios and combination of HPMC,
HPC, E-RS100 and E-RL100 as matrix-forming polymers.
All formulations carried 8% v/w of d-limonene as a penetra-
tion enhancer and 20% v/w of dibutyl phthalate as a plasti-
cizer. Formulation F5 (4:1 ratio of HPMC, E-RL100)
showed both maximum drug release (12.31 mg) and perme-
ation (2987.67 lg/cm2) in 24 h, which differed signiﬁcantly
among all the formulations. Formulation F5 showed maxi-
mum ﬂux (32.80 lg/h/cm2), which meets the ﬂux requirements,
and differed signiﬁcantly among all the formulations. A shelf
life of 2 years was predicted for the prepared TTS. The authors
claimed that, monolithic matrix-type CVD-TTS could be pre-
pared having both the required ﬂux and suitable mechanical
properties by using aforesaid polymer (Gannu et al., 2008a).
Recently, matrix-type transdermal patch of CVD was
developed using different ratios of polymer combinations by
solvent evaporation technique. It was observed that the
molded patch followed Higuchi kinetics release pattern and
the mechanism of release was found to be diffusion mediated.
The pharmacokinetic studies of optimized transdermal CVD
patches on rats revealed improved bioavailability of 72% in
comparison to oral administration with steady-state plasma
concentration. In addition optimized patch shows transdermal
ﬂux of 30.08 lg/cm2/h which was more as compared to plain
CVD, further pharmacodynamic activity of the optimized
transdermal CVD patch showed signiﬁcant controlled hyper-
tension as compared to the control group (Kshirsagar et al.,
2012). In another study, the patches containing glycyrrhizin–
chitosan mixture was also found to be able to control hyper-
tension in experimental hypertensive rats (Sapra et al., 2008).
In this study, the inﬂuence of glycyrrhizin and chitosan on
the permeation of CVD via rat epidermis was evaluated. The
permeation of CVD across excised rat epidermis was found
signiﬁcantly higher when glycyrrhizin, chitosan, or glycyrrhi-
zin–chitosan mixture was used as a donor vehicle as compared
to propylene glycol:ethanol (7:3) mixture. In addition, devel-
oped patches containing glycyrrhizin–chitosan mixture showed
sustained release of CVD, which was able to control the hyper-
tension in experimental hypertensive rats. Rat epidermis
microconstituents determination exhibit maximum extraction
of cholesterol, sphingosine, and triglycerides after treatment
with glycyrrhizin–chitosan mixture. Further, increase in inter-
cellular space, disordered lipid structure and corneocyte
detachment as observed in scanning electron microscopy
(SEM) and transmission electron microscopy (TEM) suggests
great potential of glycyrrhizin for use as a transdermal perme-
ation enhancer (Sapra et al., 2008), while extraction of lipids
from SC as well as loosening of hydrogen bonds between cera-
mides as the mechanism of enhancement of CVD by black cu-
min oil was reported elsewhere (Amin et al., 2008).
In another report, a signiﬁcant improvement in the bio-
availability of CVD was observed with the transdermal
patches over oral tablets. In this study, the bioavailability of
two drugs viz. CVD and hydrochlorothiazide from a TTS with
conventional immediate release oral tablets in healthy volun-
teers was observed. The developed TTS produced therapeuti-
cally effective plasma concentrations of the CVD and
hydrochlorothiazide up to a range of 60–72 h. In conclusion,
the developed TTS conforms to the aim of at least 2 day man-
agement of stage II hypertension with the application of a
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ance (Agrawal and Aggarwal, 2010).
Sapra et al., 2009a, investigated the effect of soybean ex-
tract and chitosan in facilitating the permeation of CVD across
the rat epidermis. The antihypertensive activity of the patches
in comparison to that after oral administration of CVD was
studied in deoxycorticosterone acetate-induced hypertensive
rats. The in vitro permeation of CVD across rat epidermis in-
creased and was maximum with a combination of soybean ex-
tract and chitosan. Furthermore, the application of patches
containing soybean extract and chitosan mixture resulted in
sustained release of CVD, which was able to control the blood
pressure in hypertensive rats through 24 h (Sapra et al., 2009a).
In another report, the effect of Asparagus racemosus extract
and chitosan in facilitating the permeation of CVD across
rat epidermis was also observed by Sapra et al., 2009b. It
was observed that the permeation of CVD via rat epidermis
was signiﬁcantly higher when Asparagus racemosus and chito-
san alone or their admixture was used as donor vehicle as com-
pared to the propylene glycol/ethanol (7:3) mixture. In
addition, the application of patches comprising Asparagus rac-
emosus extract and chitosan mixture was able to control the
blood pressure in experimental hypertensive rats over 36 h
(Sapra et al., 2009b).
Dixit et al., 2008 prepared the nanoemulsion system for
increasing the solubility and the in vitro transdermal delivery
of CVD. Transdermal permeation of CVD through the rat
skin was determined using the Keshary–Chien diffusion cell.
Authors claimed that there was a signiﬁcant increase in the
steady state ﬂux and permeability coefﬁcient in nanoemulsion
formulations as compared to the control. The highest value of
these permeability parameters was obtained in optimized for-
mulation B3 (CVD (0.5% w/w), OA (6% w/w): isopropyl myr-
istate (1:1), Tween 80 (22.5% w/w), Transcutol-P (22.5% w/w)
and distilled water. It was suggested that the prepared formu-
lation was found to be devoid of any skin irritation potential.
Consequently, in 2010, Rizwan et al. prepared nanoemul-
sion or enhanced transdermal delivery of CVD. It was ob-
served that prepared nanoemulsions showed a high skin
permeation rate (92.251–161.53 lg/cm2/h), good enhancement
ratio (ER) of 3.5–6.2 and high permeability coefﬁcient in com-
parison to control. The optimised nanoemulsion formulation
consisted of 0.25% w/w CVD, 12.5% w/w Miglyol 810,
50% w/w Acconon CC6/CO-20 (1:1) and water. The above
formulation had the smallest mean globule size of 9.28 nm.
The authors claimed that superior transdermal ﬂux of CVD
may be due to nano range size of oil globules that lead to inti-
mate contact with the skin layer. It was suggested that the
developed nanoemulsion system is a promising vehicle for
the transdermal delivery of CVD (Rizwan et al., 2010).
In another report, the effect of vehicles (labrasol, transcu-
tol, polyethylene glycol 400, propylene glycol, ethanol, OA,
and isopropyl myristate) and selected penetration enhancers
such as limonene, carvone, camphor, menthol, transcutol,
and labrasol at 5% w/v concentrations was investigated on
the in vitro permeation of CVD from saturated solutions
across porcine skin. Phosphate buffered saline (pH 7.4) con-
taining 40% v/v polyethylene glycol 400 was served as the con-
trol. It was observed that the transdermal ﬂux of CVD from
transcutol, labrasol, polyethylene glycol 400, ethanol, and
OA was 10.5, 8.6, 4.2, 2.9, and 1.5 times higher, respectively,
than that of the control. The ﬂux obtained using transcutolwas signiﬁcantly higher than the ﬂux obtained using the other
vehicles. Solutions containing camphor (5% w/v) showed max-
imum permeation in 24 h with a ﬂux of 3.19 lg/cm2/h, which
was signiﬁcantly different than the ﬂux obtained using other
permeation enhancers. The ﬂux of CVD from the solutions
containing 5% w/v camphor, limonene, transcutol, carvone,
labrasol, and menthol were 9.7, 7.6, 7.6, 6.3, 4.7, and 2.3 times
higher, respectively, than the control. The authors claimed that
transcutol, labrasol, and polyethylene glycol 400 may be used
as potential vehicles and camphor, limonene, and transcutol at
a 5% w/v level as penetration enhancers can be used for en-
hanced transdermal delivery of CVD (Gannu et al., 2008b).4.2. Labetalol
LHCL is a nonselective blocker of adrenergic receptors. It
binds competitively with both a- and b-receptors. It is slightly
soluble in water and is well absorbed from the gastrointestinal
tract. LHCL is rapidly absorbed following an oral dose but
undergoes extensive ﬁrst pass metabolism, resulting in only
25% oral bioavailability (MacCarthy and Bloomﬁeld, 1983).
The drug is eliminated rapidly, so repeated daily administra-
tion is required to maintain effective plasma levels. The half-
life of LHCL is approximately 4–6 h. It has a low molecular
weight (364.9) and favorable logP (1.89), with no reported skin
irritation history. All these factors suggest that LHCL is an
ideal drug candidate for the development of a TTS (Zafar
et al., 2010). However, fewer reports were found in the litera-
ture on the transdermal delivery of this drug. In 2005, Aqil
et al., used E-RL100, E-RS100 and PVP K-30 as the ﬁlm-
forming polymers for the preparation of matrix-type TTS of
LHCL along with polyethylene glycol-400 as the plasticizer
and DMSO as the penetration enhancer (Aqil et al., 2005).
The authors claimed a high release >90% of LHCL from
the TTS, which is therapeutically effective in experimental
hypertensive rats. In another report, Zafar et al., 2010 investi-
gated the effect of different penetration enhancers namely tur-
pentine oil, dimethyl formamide, menthol, DMSO, pine oil,
and 2-pyrollidone for LHCL transdermal delivery. Amongst
the investigated enhancers, DMSO (10% v/v) was found to
be the most effective enhancer for LHCL. It was observed that
on increasing the concentration of drug and enhancer in the
donor cell the permeability coefﬁcient of LHCL was also
accentuated. It was concluded that LHCL could be delivered
via the dermal route with the use of 10% DMSO as the pene-
tration enhancer (Zafar et al., 2010). The effect of basil oil, a
volatile oil containing alcoholic terpenes, as a potential pene-
tration enhancer for improved skin permeation of LHCL with
reference to camphor, geraniol, thymol, and clove oil was also
studied (Jain et al., 2008). In vitro permeation of LHCL in
vehicle per se and in the presence of 5% w/v enhancer was
investigated by performing in vitro rat abdominal skin perme-
ation studies using a side-by-side glass diffusion cell. Among
all enhancers, basil oil produced the maximum enhancement
(ER = 46.52) over neat vehicle. Activation energies for LHCL
permeation in water, vehicle per se and in the presence of 5%
w/v basil oil were found to be 23.16, 18.71, and 10.98 kcal/mol,
respectively. Lowering of activation energy in the presence of
basil oil suggests the creation of new polar pathways in the
skin for enhanced permeation of LHCL. It was concluded that
basil oil was found to be a promising transdermal permeation
Systemic delivery of b-blockers via transdermal route for hypertension 599enhancer for improved LHCL transdermal drug delivery. In
another report, a matrix type TTS containing combinations
of E-EPO/E-RL100 and Plasdone S630 as polymers was inves-
tigated for enhanced transdermal delivery of LHCL (Mittal
et al., 2009). The optimized formulation was also assessed
for its pharmacokinetic, pharmacodynamic, skin irritation po-
tential, and stability studies. The authors claimed 92.43% and
76.24% drug release and permeation respectively in 48 h from
the optimized patch formulation. The developed optimized
patch showed sustained action and was seemingly free of skin
irritation potential as suggested by the skin Draize score test. It
was reported that the above transdermal system holds promise
for improved bioavailability and better management of hyper-
tension on a long term basis.
5. Conclusion
Hypertension is an important predictor of cardiovascular dis-
ease, cerebrovascular accidents and death. The prevalence of
cardiovascular diseases and hypertension is rapidly increasing
in developing countries. There are many categories of antihy-
pertensives, amongst which b-blockers are a very important
class. Most b-blockers exhibit low bio availability due to hepa-
tic ﬁrst-pass metabolism following oral administration. They
are required to be taken more than once a day due to their
short half-lives. For this reason, their administration more
than once a day with the conventional oral dosage forms, such
as tablets and capsules, results in poor patient compliance.
Also, ﬂuctuations in the plasma drug concentrations are ob-
served over the dosing intervals. There is a need to improve
drug delivery devices for b-blockers because of the quantum
of their utilization and short comings associated with their
conventional dosage forms. Transdermal drug delivery systems
are one of the most rapidly advancing areas of novel drug
delivery, which are designed to deliver a therapeutically effec-
tive amount of drug across a patient’s skin. In addition, trans-
dermal delivery provides many advantages like avoidance of
the ﬁrst-pass effect, sustained therapeutic action and improved
patient compliance (Ahad et al., 2014). As we can see from this
review article, a brief overview of the different b-blockers re-
vealed that, delivering through the transdermal route improves
bioavailability as well as improves patient compliance by many
fold. Further work is needed to allow the b-blockers for trans-
dermal systems and reﬁne it in order to attain suitable clinical
levels in patients.Acknowledgement
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